Trial reportJournal of pain and symptom management2026
Results of a Randomized Phase 2 Trial of One Versus Two 8 Gy Fractions for Painful Bone Metastases.
Trial report in Journal of pain and symptom management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
contextSingle-fraction 8 Gy palliative radiotherapy (RT) is a standard regimen for the relief of painful bone metastases. However, the delivery of single-fraction RT may result in higher retreatment rates compared to longer courses.
objectivesTo compare 6‑month retreatment rates after 8 Gy x 1 versus 8 Gy x 2 and evaluate pain response, quality of life, and adverse events (AEs).
methodsIn this prospective, randomized, multi-center phase 2 trial, adults with painful bone metastases were randomized to 8 Gy x 1 (arm 1) or 8 Gy x 2 (arm 2). The primary endpoint was the 6-month cumulative incidence of retreatment, with death as a competing risk. Secondary endpoints included pain response, adverse events, and quality of life using multiple patient-reported outcome measures.
resultsA total of 102 patients were randomized and treated (51 per arm). The 6-month retreatment rates were 11.5% in arm 1 v. 10.3% in arm 2 (p = 1.00). The cause-specific hazard ratio of retreatment in arm 2 (v. arm 1) was 0.87 (p = .83). Rates of death without retreatment at 6-months were 23.3% and 29.4%, respectively. Pain response rates at 3 months were similar between arms: 55% v. 72% in arms 1 v. 2, respectively (p = .20). No substantial differences in QOL were observed between groups. Grade 2+ AEs occurred in 13.7% and 15.7% (p = .78).
conclusionNo differences were observed in retreatment rates, pain response, or QOL between 8 Gy x 1 and 8 Gy x 2. Single-fraction palliative RT remains a standard for patients with painful bone metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.